Lam Research Director Bethany Mayer Sells $174K in Shares Under 10b5-1 Plan
LAM RESEARCH CORP
Subscribe to track LRCX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
📊 Insider Sale Alert: Lam Research Corp ($LRCX) Insider: Bethany Mayer (Director) Transaction: Sold 719 shares of Common Stock at $242.59 per share (~$174,422) Plan: Rule 10b5-1 (Adopted Nov 12, 2025) Post-Transaction Holdings: 916 direct shares (plus 20,995 shares held indirectly in trust) Significance: Low
Comprehensive Analysis
Executive Summary
On November 2, 2026, Lam Research Corp ($LRCX) Director Bethany Mayer executed a scheduled sale of 719 shares of common stock at an average price of $242.59 per share, totaling approximately $174,422. The transaction was carried out pursuant to a pre-established Rule 10b5-1 trading plan.
Transaction Breakdown
- Date of Transaction: November 2, 2026
- Shares Sold: 719 shares
- Price per Share: $242.59
- Gross Proceeds: $174,422.21
- Filing Form Type: Form 4
- Trading Plan: Executed under a Rule 10b5-1 trading plan adopted on November 12, 2025.
Holdings Context
Following the transaction, Director Bethany Mayer directly retains 916 shares of common stock. Additionally, she holds 20,995 shares indirectly through a trust. The 719 shares sold represent approximately 3.3% of her combined holdings (21,911 shares retained post-sale).
Market & Governance Implications
Given that the sale represents a minor portion of the insider's total equity position and was executed pursuant to a pre-scheduled Rule 10b5-1 plan adopted nearly a year prior, this activity carries low trading significance and reflects routine liquidity management rather than a discretionary signal on company performance.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.
